Other Solid Tumor Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Other Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Breast CancerOvarian CancerColorectal Carcinoma+4 more
AstraZeneca46 enrolled18 locationsNCT05877599
Recruiting
Phase 1Phase 2

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Colorectal, CancerCutaneous MelanomaOther Solid Tumors+1 more
IDEAYA Biosciences336 enrolled15 locationsNCT03947385
Recruiting
Phase 1Phase 2

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

Anaplastic Large Cell Lymphoma, ALK-PositiveInflammatory Myofibroblastic TumorOther Solid Tumor
Princess Maxima Center for Pediatric Oncology65 enrolled2 locationsNCT04925609
Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Biliary Tract CancerEsophageal AdenocarcinomaGastric Adenocarcinoma+2 more
SystImmune Inc.120 enrolled17 locationsNCT07021066
Recruiting
Phase 1

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

Prostate CancerEwing SarcomaOther Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.110 enrolled3 locationsNCT06926283
Recruiting
Phase 2

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.350 enrolled1 locationNCT06947291
Recruiting
Phase 1Phase 2

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316
Recruiting
Phase 1

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
Shanghai Junshi Bioscience Co., Ltd.214 enrolled13 locationsNCT06839105
Recruiting
Early Phase 1

Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

Pancreatic NeoplasmsOther Solid Tumors
Ruijin Hospital56 enrolled1 locationNCT06577532
Recruiting
Phase 1Phase 2

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Cervical CancerProstate CancerUrothelial Carcinoma+5 more
Evopoint Biosciences Inc.204 enrolled1 locationNCT06022757